Objective To systematically review the clinical response and partial adverse effects of endostar plus chemotherapy for patients with unresected non small cell lung cancer.
Methods The clinical trials of endostar plus chemotherapy for unresected non small cell lung cancers published before March 2, 2010 were searched in The Cochrane Library, Medline, EMbase, Pubmed, CBM, CNKI, VIP and so on. According to the Cochrane handbook for systematic reviews for interventions, the quality of clinical trials was evaluated by two reviewers independently, and the meta-analysis was conducted by using Revman 5.0 software.
Results The endostar as an endostatin was developed by our country, so the relevant RCTs were not found in foreign databases. Fourteen studies involving 1 219 patients were included. All studies adopted random method but no blind method was mentioned in detail. The results of meta-analysis indicated that the rate of clinical response and clinical benefit of the endostar plus chemotherapy group was significantly higher than that of the chemotherapy alone group (RR=1.76, 95%CI 1.47 to 2.09; RR=1.43, 95%CI 1.10 to1.86; respectively). The incidence rate of thrombocytopenia was significantly lower of the endostar plus chemotherapy group than that of the chemotherapy alone group (RR=0.77, 95%CI 0.62 to 0.96). The incidence rates of hypoleukemia, anaemia, nausea and vomiting and hepatic and renal function damage were not significantly different between the two groups (RR=0.94, 95%CI 0.83 to 1.06; RR=0.94, 95%CI 0.79 to 1.13; RR=1.04, 95%CI 0.91 to 1.18; RR=0.63, 95%CI 0.25 to 1.60; respectively).
Conclusion Endostar plus chemotherapy can improve the rate of clinical response and clinical benefit, and can relieve partial adverse effects of chemotherapy.
Citation： ZHAO Weigang,HU Shilian,SHEN Gan,WANG Feng. Endostar plus Chemotherapy for Non Small Cell Lung Cancer: A Systematic Review. Chinese Journal of Evidence-Based Medicine, 2011, 11(10): 1144-1150. doi: 10.7507/1672-2531.20110193 Copy